Chimeric mMSLN-VLP vaccination reduced tumor burden and prolonged survival in a Panc02-bearing orthotopic pancreatic cancer mouse model.
Panc02 cells (7×105) were orthotopically implanted at pancreas of 8-week old C57BL/6 mice at day 0. Three immunizations at days 3, 13, and 21 were applied by i.p. route with different VLPs. The mice were divided in three groups which immunized with either 100 µl of PBS, or 100 µg/100 µl of SIV-VLP, or 100 µg/100 µl of MSLN-VLP. A). Reduced tumor burden in mMSLN-VLPs immunized groups. Tumor size between each group was statistically compared by student t-test. *p<0.05. B). Prolonged survival of mMSLN-VLPs immunized mice groups Kaplan-Meier Survival Analysis. P values were calculated and listed on the figure. These were representative data selected from four independent experiments with A) five or B) at least 9 mice per group.